ATC code L
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
WikiDoc Resources for ATC code L |
Articles |
---|
Most recent articles on ATC code L |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on ATC code L at Clinical Trials.gov Clinical Trials on ATC code L at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on ATC code L
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on ATC code L Discussion groups on ATC code L Patient Handouts on ATC code L Directions to Hospitals Treating ATC code L Risk calculators and risk factors for ATC code L
|
Healthcare Provider Resources |
Causes & Risk Factors for ATC code L |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
A section of the Anatomical Therapeutic Chemical Classification System.
L Antineoplastic and immunomodulating agents
Template:SIB gl:Código ATC L hu:ATC L – Daganatellenes szerek és immunmodulátorok th:ATC รหัส L